EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC
EGFR mutation testing in non-small cell lung cancer (NSCLC) is a novel and important molecular pathological diagnostic assay that is predictive of response to anti-epidermal growth factor receptor (EGFR) therapy. A comprehensive compilation of a large number of EGFR mutation analyses of the German P...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2011
|
| In: |
Virchows Archiv
Year: 2011, Volume: 458, Issue: 1, Pages: 95-98 |
| ISSN: | 1432-2307 |
| DOI: | 10.1007/s00428-010-1000-y |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00428-010-1000-y |
| Author Notes: | Roland Penzel, Christine Sers, Yuan Chen, Ulrich Lehmann-Mühlenhoff, Sabine Merkelbach-Bruse, Andreas Jung, Thomas Kirchner, Reinhard Büttner, Hans H. Kreipe, Iver Petersen, Manfred Dietel, Peter Schirmacher |
| Summary: | EGFR mutation testing in non-small cell lung cancer (NSCLC) is a novel and important molecular pathological diagnostic assay that is predictive of response to anti-epidermal growth factor receptor (EGFR) therapy. A comprehensive compilation of a large number of EGFR mutation analyses of the German Panel for Mutation Analyses in NSCLC demonstrates (a) a higher than previously reported mutation frequency outside the conventionally tested exons 19 and 21 and (b) an overall superiority of sequencing based assays over mutation-specific PCR. The implications for future diagnostic EGFR mutation testing are discussed. |
|---|---|
| Item Description: | Published online: 06 November 2010 Gesehen am 19.10.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1432-2307 |
| DOI: | 10.1007/s00428-010-1000-y |